Cmax Cmin
Cmax Cmin - Related Videos
07:23
Construction and Testing of Coin Cells of Lithium Ion Batteries
0 Views •
Cited by 13 •
2012
A protocol to construct and test coin cells of lithium ion batteries is described. The specific procedures of making a working electrode, preparing a counter electrode, assembling a cell inside a glovebox and testing the cell are presented.
12:28
Non-aqueous Electrode Processing and Construction of Lithium-ion Coin Cells
0 Views •
Cited by 11 •
2016
Non-aqueous electrode processing is central to the construction of coin cells and the evaluation of new electrode chemistries for lithium-ion batteries. A step-by-step guide to the basic practices needed as an electrochemical engineer working with batteries in an academic experimental setting is furnished.
09:07
Electrophysiological Motor Unit Number Estimation (MUNE) Measuring Compound Muscle Action Potential (CMAP) in Mouse Hindlimb Muscles
0 Views •
Cited by 86 •
2015
We present refined protocols that allow in vivo monitoring of motor unit function in the mouse. Techniques to measure compound muscle action potential (CMAP) and motor unit number estimation (MUNE) in the mouse hind limb muscles innervated by the sciatic nerve are described.
07:42
Coin Cell Battery Chamber Design for Low-temperature Operando Experiments
0 Views •
Cited by 1 •
2026
A design is presented to enable cost-effective low-temperature battery cycling for 2032 coin cells in a low-humidity environment. Cells are cycled at 0 °C inside a chamber cooled by thermoelectric modules. This simple design can be adapted for experiments that require similar thermal and humidity-controlled environments or different battery geometries.
01:30
Initial Coin Offerings
0 Views •
2026
An Initial Coin Offering (ICO) is a fundraising method cryptocurrency startups use to raise capital. It allows companies to bypass traditional financial institutions like banks or venture capital firms and directly raise funds from the public. ICOs are often compared to Initial Public Offerings (IPOs) in the stock market, but investors receive digital tokens instead of shares.In an ICO, a company issues its cryptocurrency or tokens and sells them to investors in exchange for established...
FAQs
Cmax depends on how much drug reaches the circulation, how quickly it is absorbed, and how widely it distributes. Dose, absorption rate, and bioavailability therefore influence the magnitude of the peak. Comparing Cmax values can help distinguish changes in drug exposure caused by the administered amount from those associated with absorption or availability.
Cmin reflects the concentration remaining when the next dose is due, so drug elimination and the length of the dosing interval are especially important. More frequent dosing changes the time available for concentrations to decline, while slower elimination can preserve higher trough values. These relationships make Cmin useful when evaluating whether a regimen sustains adequate exposure.
Cmax emphasizes the highest observed concentration, whereas Cmin shows the residual concentration at the end of the dosing interval. Considering both values gives a broader view than either measure alone: the peak helps assess exposure associated with concentration-related toxicity, while the trough supports evaluation of sustained exposure and potential therapeutic effectiveness.
Differences in Cmax and Cmin may indicate that patients or dosing regimens produce different exposure patterns. A regimen can generate a higher peak, a different trough, or both, even when comparisons involve the same general treatment. Reviewing these measures together supports interpretation of variability, assessment of therapeutic response, and identification of concentration-related safety concerns.
Therapeutic drug monitoring uses measured drug concentrations to relate an individual patient's exposure to treatment goals and safety concerns. Assessing the peak and the pre-dose trough provides complementary information for dose optimization. Clinicians and researchers can use these results to compare observed concentrations with the exposure pattern expected from a selected regimen and consider whether adjustment is warranted.
Clinical researchers compare Cmax and Cmin across dosing regimens to characterize exposure, evaluate efficacy, and assess the risk of concentration-related toxicity. These comparisons can inform dose optimization and contribute to the design of treatments that balance therapeutic benefit with safety. The measures also provide pharmacokinetic context for interpreting how dosing choices affect blood or plasma concentrations.